Ryan Arthur F's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Feb 11, 2026
- Accession no.
- 0001187443-26-000004
- Filed
- Feb 11, 2026
- Trade date
- Feb 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 13 non-derivative transactions. Open-market sales total $77.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ryan Arthur FCIK 0001187443 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $775.63 | −$775.63 | 17,902 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −10 | $776.59F2 | −$7,765.9 | 17,892 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −57 | $777.56F3 | −$44,320.92 | 17,835 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −12 | $778.53F4 | −$9,342.36 | 17,823 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −5 | $779.41F5 | −$3,897.05 | 17,818 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $780.09 | −$780.09 | 17,817 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −5 | $781.48F6 | −$3,907.4 | 17,812 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $782.53 | −$782.53 | 17,811 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −3 | $783.34F7 | −$2,350.02 | 17,808 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $784.59 | −$784.59 | 17,807 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $785.71 | −$785.71 | 17,806 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −2 | $786.29 | −$1,572.58 | 17,804 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −1 | $787.82 | −$787.82 | 17,803 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F7
Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.